Lipoxins, Resolvins, Protectins, Maresins, and Nitrolipids: Connecting Lipids, Inflammation, and Cardiovascular Disease Risk

被引：19
作者：
Das U.N. [1 ,2 ]
机构：
[1] Jawaharlal Nehru Technological University, Kakinada
[2] UND Life Sciences, Shaker Heights, OH, 44120, 13800 Fairhill Road
来源：
Current Cardiovascular Risk Reports | 2010年 / 4卷 / 1期
关键词：
Atherosclerosis; Coronary heart disease; Lipoxins; Maresins; Nitrolipids; Platelets; Polyunsaturated fatty acids; Protectins; Resolvins;
D O I：
10.1007/s12170-009-0068-x
中图分类号：
学科分类号：
摘要：
Essential fatty acids and their metabolites (γ-linolenic acid [GLA], dihomo-GLA, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid; prostaglandin E1; prostacyclin [PGI2]; PGI3; lipoxins; resolvins; protectins; maresins; and nitrolipids) prevent platelet aggregation, produce vascular relaxation, inhibit neutrophil degranulation and superoxide formation, inhibit platelet activation, possess peroxisome proliferator-activated receptor-γ ligand activity, and release nitric oxide. Thus, they lower blood pressure, are anti-arrhythmic and anti-inflammatory in nature, reduce low-density lipoprotein cholesterol, ameliorate the adverse actions of homocysteine, activate telomerase, and have cytoprotective properties-actions that prevent atherosclerosis and cardiovascular disease. Because coronary heart disease (CHD) and atherosclerosis are low-grade systemic inflammatory conditions, it is likely that reduced formation of lipoxins, resolvins, protectins, maresins, and nitrolipids plays a significant role in the pathogenesis of CHD. Hence, development of stable synthetic analogues of lipoxins, resolvins, protectins, and maresins may form a new therapeutic approach to CHD and other low-grade systemic inflammatory conditions. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：24 / 31
页数：7
相关论文
共 55 条
[1]  
Wald N.J., Law M.R., A strategy to reduce cardiovascular disease by more than 80%, Bmj, 326, (2003)
[2]  
Das U.N., Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease, Prostaglandins Leukot Essent Fatty Acids, 52, pp. 387-391, (1995)
[3]  
Nutritional factors in the pathobiology of human essential hypertension, Nutrition, 17, pp. 337-346, (2001)
[4]  
A defect in the activity of delta6 and delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome, Prostaglandins Leukot Essent Fatty Acids, 72, pp. 343-350, (2005)
[5]  
Mozaffarian D., Ascherio A., Hu F.B., Et al., Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men, Circulation, 111, pp. 157-164, (2005)
[6]  
Essential fatty acids-a review, Curr Pharm Biotechnol, 7, pp. 467-482, (2006)
[7]  
Can essential fatty acids reduce the burden of diseases?, Lipids Health Dis, 7, (2008)
[8]  
Cross talk among leukocytes, platelets, and endothelial cells and its relevance to atherosclerosis and coronary heart disease, Current Nutr Food Sci, 5, pp. 75-93, (2009)
[9]  
Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease?, Lipids Health Dis, 7, (2008)
[10]  
Levine L., Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells, Lipids Health Dis, 2, (2003)
123456